Presentation highlights study-enrollment challenges and strategies to overcome potential barriers "Data from clinical studies of repetitive seizures in early childhood are critical to help advance new ...

Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will join the epilepsy community at Epilepsy Awareness Day at Walt Disney World, one of the largest and first ...

TURKU, FINLAND--(Marketwired - Jun 4, 2013) - Biotie Therapies Corp. ("Biotie") today announced that it has obtained an exclusive option to acquire Neurelis, Inc. ("Neurelis"), a private specialty ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of acute repetitive seizures, also referred to as seizure clusters, in ...

-- Funds to be utilized to complete development work and begin commercialization preparations for NRL-1. Program has received Orphan Drug and Fast Track Designation from FDA. "We are very excited to ...

Neurelis, Inc., a commercial-stage neuroscience company, announced the first two cohorts dosed in the investigational clinical trial of NRL-1049, a Rho kinase (ROCK) inhibitor, a potential treatment ...

As Neurelis awaits an FDA decision on its flagship drug, the company has launched its first seizure awareness campaign. Neurelis is hoping for an approval for nasal spray Valtoco to treat epilepsy ...

Acceptance of Investigational New Drug Application is another significant milestone in the effort to address the significant need for a therapy for acute repetitive seizures outside of the hospital ...

SAN DIEGO, March 2, 2023 /PRNewswire/ -- Neurelis, Inc. is proud to announce the 'Give Seizures the Sprayer' marketing campaign for VALTOCO® (diazepam nasal spray) CIV has won a 2023 PM360 Pharma ...

SAN DIEGO, Aug. 18, 2022 /PRNewswire/ -- Neurelis, Inc., is pleased to announce it has been named one of the Best Places to Work in SoCal 2022 by Best Companies Group (BCG), a BridgeTower Media ...

SAN DIEGO, Nov. 11, 2024 /PRNewswire/ -- Neurelis, Inc., today announced a presentation on insights into study design from the enrollment process for the new Stellina study investigating VALTOCO® ...